Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q2

2372.TEDINET S100PFYJ
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥9.6bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥15.7bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥6.8bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.4bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥858m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥2.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥2.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥994m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥2.6bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥1.0bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥723m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥721m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥30.4bnat 2022-09-30Cons.Assets
Total assets¥26.6bnat 2022-03-31Cons.Assets
Total assets¥22.7bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥18.5bnat 2022-09-30Cons.Liabilities
Total liabilities¥16.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥12.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥10.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.0bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥7.0bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥6.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥7.0bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥6.4bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥5.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥653m2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥2.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥740m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥2.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥164.172022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥75.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥162.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.992021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.52021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥163.912022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥162.172021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥59.852021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio39.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥68m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥118m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥673m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2022-04-01 → 2022-09-30¥619m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥618m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2022-04-01 → 2022-09-30−¥181m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥88m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-09-30¥82m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥953m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥503m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥449m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥24m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-09-30¥5.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.7bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥61m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥10.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥601m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥641m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥32m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥8m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥100m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥492m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥492m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥658m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2021-04-01 → 2021-09-30¥294m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2021-04-01 → 2021-09-30¥291m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥2m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2021-04-01 → 2021-09-30−¥311m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2021-04-01 → 2021-09-30¥2.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥29m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2021-04-01 → 2021-09-30¥240m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2021-04-01 → 2021-09-30¥856m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2021-04-01 → 2021-09-30¥497m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥359m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2021-04-01 → 2021-09-30¥123m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2021-04-01 → 2021-09-30¥3.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.7bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥77m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.6bn
—segment totalrevenue2021-04-01 → 2021-09-30¥7.3bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥6.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥468m
—segment totalsegment profit2021-04-01 → 2021-09-30¥1.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥7.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥6.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥492m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 548
ItemContextValueUnit
Non controlling interestsPrior1YearInstant16000000JPY
Non controlling interestsCurrentQuarterInstant25000000JPY
Net assetsPrior1YearInstant10162000000JPY
Net assetsCurrentQuarterInstant11967000000JPY
Liabilities and net assetsPrior1YearInstant26588000000JPY
Liabilities and net assetsCurrentQuarterInstant30433000000JPY
Net salesPrior1YTDDuration6839000000JPY
Net salesCurrentYTDDuration9639000000JPY
Cost of salesPrior1YTDDuration3885000000JPY
Cost of salesCurrentYTDDuration4613000000JPY
Gross profitPrior1YTDDuration2953000000JPY
Gross profitCurrentYTDDuration5026000000JPY
Directors compensations sgaPrior1YTDDuration242000000JPY
Directors compensations sgaCurrentYTDDuration241000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration761000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration1019000000JPY
Commission fee sgaPrior1YTDDuration83000000JPY
Commission fee sgaCurrentYTDDuration89000000JPY
Rent expenses sgaPrior1YTDDuration135000000JPY
Rent expenses sgaCurrentYTDDuration202000000JPY
Research and development expenses sgaPrior1YTDDuration318000000JPY
Research and development expenses sgaCurrentYTDDuration371000000JPY
Other sgaPrior1YTDDuration553000000JPY
Other sgaCurrentYTDDuration692000000JPY
Selling general and administrative expensesPrior1YTDDuration2095000000JPY
Selling general and administrative expensesCurrentYTDDuration2616000000JPY
Operating incomePrior1YTDDuration858000000JPY
Operating incomeCurrentYTDDuration2409000000JPY
Gain on sales of investment securities noiPrior1YTDDuration183000000JPY
Gain on sales of investment securities noiCurrentYTDDuration－JPY
Interest income noiPrior1YTDDuration14000000JPY
Interest income noiCurrentYTDDuration4000000JPY
Dividends income noiPrior1YTDDuration5000000JPY
Dividends income noiCurrentYTDDuration0JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration349000000JPY
Other noiPrior1YTDDuration29000000JPY
Other noiCurrentYTDDuration110000000JPY
Non operating incomePrior1YTDDuration233000000JPY
Non operating incomeCurrentYTDDuration465000000JPY
Interest expenses noePrior1YTDDuration46000000JPY
Interest expenses noeCurrentYTDDuration64000000JPY
Loss on investment of securities noePrior1YTDDuration3000000JPY
Loss on investment of securities noeCurrentYTDDuration181000000JPY
Foreign exchange losses noePrior1YTDDuration19000000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY
Commission fee noePrior1YTDDuration27000000JPY
Commission fee noeCurrentYTDDuration124000000JPY
Other noePrior1YTDDuration0JPY
Other noeCurrentYTDDuration1000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass